CTOs on the Move

Targacept

www.targacept.com

 
Targacept`s clinical pipeline is built on a unique class of therapeutic targets.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.targacept.com
  • 100 N Main St Ste 1510
    Winston Salem, NC USA 27101
  • Phone: 336.480.2100

Executives

Name Title Contact Details

Similar Companies

healthchemdiagnostics

healthchemdiagnostics is a Pompano Beach, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Genomenon

Genomenon is an AI-driven genomics company whose mission is to save and improve lives by making genomic information actionable for patients with rare genetic diseases and cancer.

Ring Therapeutics

Ring`s research team has uncovered the world`s largest collection of commensal anelloviruses and are harnessing these natural viruses to target a wide array of diseases with significant unmet need. The unique biology of anelloviruses provides a foundation for a revolutionary new platform and a new class of programmable medicines.

Baptist Retirement Communities of Georgia

Baptist Retirement Communities of Georgia is a Decatur, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Angion

Angion Biomedica Corp. is a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion`s lead product candidate, ANG-3777, is a small molecule designed to mimic the biological activity of hepatocyte growth factor (HGF) to activate the HGF/c-Met pathway, which has a central role in tissue repair and organ recovery. Enrollment is ongoing in a placebo-controlled Phase 3 registration trial examining the efficacy of ANG-3777 in reducing the severity of transplant-associated acute kidney injury, also known as delayed graft function, in patients at risk for kidney dysfunction. ANG-3777 is also in a Phase 2 clinical trial for the treatment of acute kidney injury associated with cardiac surgery involving cardiopulmonary bypass. Angion is also developing ANG-3070, an orally-bioavailable small molecule, as a potential treatment for a variety of chronic fibrotic diseases sharing similar underlying disease-driving pathways identified and targeted using a precision-medicine approach.